Ye Z, Zeng Y, Wei S, et al. - Via this single-arm phase II trial, researchers examined the short-term efficacy as well as safety of apatinib combined with oxaliplatin and S-1 in the treatment of unresectable gastric malignancy. Participants were previously untreated patients suffering from unresectable HER-2-negative advanced gastric cancer. All participants were treated with six cycles of S-1 and oxaliplatin and five cycles of apatinib, which were given at intervals of three weeks. Following six cycles of drug treatment, patients underwent surgery. Radical resection (R0) rate and safety were set as primary endpoints. An objective response rate and disease control rate of 73.0% and 81.1%, respectively, was achieved. Findings revealed that not only a good short-term survival was offered by apatinib combined with oxaliplatin and S-1 but also this treatment regimen showed an acceptable safety in the conversion therapy of unresectable gastric cancer.